Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1975 2
1976 1
1978 1
1980 1
1981 1
1982 1
1983 3
1984 5
1985 4
1986 6
1987 7
1988 12
1989 12
1990 18
1991 29
1992 31
1993 20
1994 48
1995 46
1996 52
1997 51
1998 62
1999 51
2000 71
2001 69
2002 78
2003 111
2004 106
2005 103
2006 113
2007 135
2008 105
2009 123
2010 130
2011 132
2012 143
2013 163
2014 187
2015 170
2016 172
2017 157
2018 160
2019 146
2020 156
2021 180
2022 173
2023 186
2024 60

Text availability

Article attribute

Article type

Publication date

Search Results

3,462 results

Results by year

Filters applied: . Clear all
Page 1
Treatment of Advanced Prostate Cancer.
Teo MY, Rathkopf DE, Kantoff P. Teo MY, et al. Annu Rev Med. 2019 Jan 27;70:479-499. doi: 10.1146/annurev-med-051517-011947. Annu Rev Med. 2019. PMID: 30691365 Free PMC article. Review.
The therapeutic landscape of prostate cancer has been transformed over the last decade by new therapeutics, advanced functional imaging, next-generation sequencing, and better use of existing therapies in early-stage disease. Until 2004, progression on …
The therapeutic landscape of prostate cancer has been transformed over the last decade by new therapeutics, advanced fu …
High-risk prostate cancer-classification and therapy.
Chang AJ, Autio KA, Roach M 3rd, Scher HI. Chang AJ, et al. Nat Rev Clin Oncol. 2014 Jun;11(6):308-23. doi: 10.1038/nrclinonc.2014.68. Epub 2014 May 20. Nat Rev Clin Oncol. 2014. PMID: 24840073 Free PMC article. Review.
Approximately 15% of patients with prostate cancer are diagnosed with high-risk disease. However, the current definitions of high-risk prostate cancer include a heterogeneous group of patients with a range of prognoses. ...This Review critically evalua …
Approximately 15% of patients with prostate cancer are diagnosed with high-risk disease. However, the current definitions of h …
Modern paradigms for prostate cancer detection and management.
Williams IS, McVey A, Perera S, O'Brien JS, Kostos L, Chen K, Siva S, Azad AA, Murphy DG, Kasivisvanathan V, Lawrentschuk N, Frydenberg M. Williams IS, et al. Med J Aust. 2022 Oct 17;217(8):424-433. doi: 10.5694/mja2.51722. Epub 2022 Oct 2. Med J Aust. 2022. PMID: 36183329 Free PMC article. Review.
The management of advanced prostate cancer treatment has evolved to now include several novel agents both in the metastatic hormone-sensitive and castration-resistant disease settings. ...PSMA-based radioligand therapy has emerged as a treatment …
The management of advanced prostate cancer treatment has evolved to now include several novel agents both in the metast …
Available evidence on HIFU for focal treatment of prostate cancer: a systematic review.
Bakavicius A, Marra G, Macek P, Robertson C, Abreu AL, George AK, Malavaud B, Coloby P, Rischmann P, Moschini M, Rastinehad AR, Sidana A, Stabile A, Tourinho-Barbosa R, de la Rosette J, Ahmed H, Polascik T, Cathelineau X, Sanchez-Salas R. Bakavicius A, et al. Int Braz J Urol. 2022 Mar-Apr;48(2):263-274. doi: 10.1590/S1677-5538.IBJU.2021.0091. Int Braz J Urol. 2022. PMID: 34003610 Free PMC article. Review.
PURPOSE: Prostate cancer (PCa) is the second most common oncologic disease among men. ...The majority of complications presented in the early postoperative period and were classified as low-grade. CONCLUSIONS: This review highlights that focal HIFU therapy …
PURPOSE: Prostate cancer (PCa) is the second most common oncologic disease among men. ...The majority of complications present …
Prostate cancer.
Castillejos-Molina RA, Gabilondo-Navarro FB. Castillejos-Molina RA, et al. Salud Publica Mex. 2016 Apr;58(2):279-84. doi: 10.21149/spm.v58i2.7797. Salud Publica Mex. 2016. PMID: 27557386 Review.
Prostate cancer is the most frequent tumor found in men worldwide and in Mexico in particular. ...This article reviews screening and diagnostic methods as well as treatment options for patients diagnosed with prostate cancer....
Prostate cancer is the most frequent tumor found in men worldwide and in Mexico in particular. ...This article reviews …
Ipilimumab for the treatment of metastatic prostate cancer.
Alaia C, Boccellino M, Zappavigna S, Amler E, Quagliuolo L, Rossetti S, Facchini G, Caraglia M. Alaia C, et al. Expert Opin Biol Ther. 2018 Feb;18(2):205-213. doi: 10.1080/14712598.2018.1420777. Epub 2017 Dec 28. Expert Opin Biol Ther. 2018. PMID: 29271259 Review.
Immunotherapy with checkpoint inhibitors is beginning to be recognized as a valid weapon for the treatment of metastatic prostate cancer (PCa) when chemotherapy fails. ...It also has a molecular weight of 148 kDa and is water-soluble at physiological pH. Ipi …
Immunotherapy with checkpoint inhibitors is beginning to be recognized as a valid weapon for the treatment of metastatic prostate …
Combining immunotherapies for the treatment of prostate cancer.
Redman JM, Gulley JL, Madan RA. Redman JM, et al. Urol Oncol. 2017 Dec;35(12):694-700. doi: 10.1016/j.urolonc.2017.09.024. Urol Oncol. 2017. PMID: 29146441 Free PMC article. Review.
Sipuleucel-T, a therapeutic dendritic-cell vaccine, was Food and Drug Administration-approved for prostate cancer in 2010. No new immunotherapies for prostate cancer have been approved since. However, novel agents and combination approaches offer great …
Sipuleucel-T, a therapeutic dendritic-cell vaccine, was Food and Drug Administration-approved for prostate cancer in 2010. No …
Sequencing Treatment for Castration-Resistant Prostate Cancer.
Handy CE, Antonarakis ES. Handy CE, et al. Curr Treat Options Oncol. 2016 Dec;17(12):64. doi: 10.1007/s11864-016-0438-9. Curr Treat Options Oncol. 2016. PMID: 27822685 Review.
Prostate cancer is the most common non-cutaneous cancer diagnosed in men and the second leading cause of male cancer deaths in the USA. While most cases are diagnosed in early stages, some will present as or progress to metastatic disease and ev …
Prostate cancer is the most common non-cutaneous cancer diagnosed in men and the second leading cause of male cancer …
Chemotherapeutic inhibitors in the treatment of prostate cancer.
Deshmukh RR, Schmitt SM, Hwang C, Dou QP. Deshmukh RR, et al. Expert Opin Pharmacother. 2014 Jan;15(1):11-22. doi: 10.1517/14656566.2014.852184. Epub 2013 Oct 25. Expert Opin Pharmacother. 2014. PMID: 24156780 Review.
Several novel agents targeting signaling pathways in prostate cancer have recently been approved by the US Food and Drug Administration (FDA) but there is still an unmet need for new treatment strategies for castration-resistant prostate cancer …
Several novel agents targeting signaling pathways in prostate cancer have recently been approved by the US Food and Drug Admin …
Drug design strategies for the treatment of prostate cancer.
Lauer RC, Friend SC, Rietz C, Pasqualini R, Arap W. Lauer RC, et al. Expert Opin Drug Discov. 2015 Jan;10(1):81-90. doi: 10.1517/17460441.2015.978855. Epub 2014 Nov 4. Expert Opin Drug Discov. 2015. PMID: 25366417 Review.
INTRODUCTION: While metastatic prostate cancer remains an incurable tumor, remarkable progress has been made with novel drug design strategies for this incurable disease. ...They also discuss the current challenges and future opportunities in the medical care of …
INTRODUCTION: While metastatic prostate cancer remains an incurable tumor, remarkable progress has been made with novel drug d …
3,462 results